ACTN1 and cancer: Notably, the potential to generate secondary PDXs was significantly reduced in tumor cells treated with a combination of ACTN1 inhibition and cisplatin, compared to the robust tumorigenicity exhibited by cancer cells receiving other individual treatments (Fig. 8D-F, Supplementary Table 5).